Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of REGN727 / SAR236553 in high cardiovascular risk patients with hypercholesterolemia
2011-002806-59Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia comparing SAR236553 (REGN727) with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jan 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2011-002806-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002806-59.